Key result
OAC discontinuation ≥6 months post-AF ablation cuts major bleeding ~67% without significantly increasing stroke.
Why the study?
The optimal long-term OAC strategy after catheter ablation for AF remains uncertain, and guideline recommendations based on thromboembolic risk scores irrespective of rhythm status have not been validated by RCTs.
Does discontinuation of oral anticoagulation reduce bleeding events without increasing all-stroke and embolism in patients who remain arrhythmia-free for at least 6 months after atrial fibrillation ablation?
Meta-Analysis (n=2,324)
Randomized controlled trials included
Does discontinuation of oral anticoagulation reduce bleeding events without increasing all-stroke and embolism in patients who remain arrhythmia-free for at least 6 months after atrial fibrillation ablation?
In patients remaining arrhythmia-free at least 6 months after AF ablation, discontinuing OAC reduces major and clinically relevant non-major bleeding without a statistically significant increase in stroke or systemic embolism.
Answers are grounded in this paper and cite their sources.
OAC discontinuation after successful AF ablation reduces major bleeding without significantly raising stroke risk; challenges indefinite anticoagulation guidelines.
Background: The optimal strategy for long-term oral anticoagulation (OAC) after catheter ablation for atrial fibrillation (AF) remains uncertain. Although current guidelines recommend anticoagulation based on thromboembolic risk scores irrespective of rhythm status, this recommendation has not been validated by randomized controlled trials (RCTs). Methods: We included three RCTs, ODIn-AF, ALONE-AF, and OCEAN, enrolling patients at least 6 months post-ablation with no recurrent atrial arrhythmias. Primary efficacy outcomes were all-stroke and embolism (including cerebral emboli). The primary safety outcome was major bleeding. Secondary outcomes included clinically relevant non-major bleeding and other thromboembolic and bleeding events. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random-effects model. Results: 2324 patients were included. Continued anticoagulation therapy did not significantly reduce the risk of all-stroke and embolism, at least 6 months post-catheter ablation [RR 0.58 (0.11-3.12); I 2 =54%]. OAC discontinuation was associated with lower risk of major bleeding [RR 0.33 (0.11-0.95); I 2 = 0%] and clinically relevant non-major bleeding [RR 0.40 (0.19-0.84); I 2 = 0%]. No significant differences were observed for other thromboembolic and bleeding events. Sensitivity analyses using per-protocol populations were significant only for a reduction in clinically relevant non-major bleeding [RR 0.33 (0.17-0.65); I 2 = 0%]. Conclusions: In patients remaining arrhythmia-free for at least 6 months after AF ablation, discontinuation of OAC reduces bleeding events without a statistically significant increase in thromboembolic risk, highlighting the need for larger, well-powered RCTs to better inform post-ablation anticoagulation strategies.
No takes yet. Share an insight, caveat, or question.
Karthikeyan et al. (2026) conducted a meta-analysis in Atrial fibrillation post-catheter ablation (n=2,324). Oral anticoagulation (OAC) discontinuation vs. Continued oral anticoagulation therapy was evaluated on All-stroke and embolism (including cerebral emboli; primary efficacy) and major bleeding (primary safety) (RR 0.58, 95% CI 0.11-3.12). OAC discontinuation ≥6 months post-AF ablation reduced major bleeding while continued OAC did not reduce stroke and embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: